REDWOOD CITY, Calif.,
June 19, 2014 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for the treatment of
acute and breakthrough pain, today announced that senior management
will present a corporate overview on June 25th. Presentation
details are as follows:
JMP Securities Healthcare Conference
Date:
Wednesday, June 25th
Location: The Westin New York Grand Central, New York
Presentation Time: 10:30am ET
This presentation will be webcast live and can be accessed
through the Investors page at www.acelrx.com. For those not
available to listen to the live broadcast, a replay will be
archived for 90 days and available through the Investors page on
www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute and breakthrough
pain. AcelRx's lead product candidate, Zalviso™, is designed to
improve the management of moderate-to-severe acute pain in adult
patients in the hospital setting by utilizing a high therapeutic
index opioid, through a non-invasive delivery route via a
pre-programmed, patient-controlled analgesia device. AcelRx
has announced positive results from each of the three completed
Phase 3 clinical trials for Zalviso, and has submitted an NDA to
the FDA seeking approval for Zalviso in the treatment of
moderate-to-severe acute pain in adult patients in the hospital
setting. AcelRx plans to initiate a Phase 3 clinical trial
for ARX-04, a product candidate for the treatment of
moderate-to-severe acute pain in a medically supervised setting,
during the second half of 2014. The company has two additional
pain treatment product candidates, ARX-02 and ARX-03, which have
completed Phase 2 clinical development. For additional
information about AcelRx's clinical programs, please visit
www.acelrx.com.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to anticipated
approval of the NDA by the FDA, planned initiation of the Phase 3
clinical trial for ARX-04, and the therapeutic potential of
AcelRx Pharmaceuticals' product candidates, including Zalviso.
These forward-looking statements are based on AcelRx
Pharmaceuticals' current expectations and inherently involve
significant risks and uncertainties. AcelRx Pharmaceuticals' actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these
risks and uncertainties, which include, without limitation, risks
related to: AcelRx Pharmaceuticals' ability to receive regulatory
approval for Zalviso; any delays or inability to obtain and
maintain regulatory approval of its product candidates, including
Zalviso, in the United States and
Europe; its ability to obtain
sufficient financing to commercialize Zalviso and proceed with
clinical development of ARX-04; the success, cost and timing of all
product development activities and clinical trials, including the
planned Phase 3 ARX-04 trial; the market potential for its product
candidates; and other risks detailed in the "Risk Factors" and
elsewhere in AcelRx Pharmaceuticals' U.S. Securities and Exchange
Commission filings and reports, including its Annual Report on Form
10-K filed with the SEC on March 17,
2014. AcelRx Pharmaceuticals undertakes no duty or
obligation to update any forward-looking statements contained in
this release as a result of new information, future events or
changes in its expectations.
Logo -
http://photos.prnewswire.com/prnh/20130226/MM67303LOGO
SOURCE AcelRx Pharmaceuticals, Inc.